Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study on the Safety and Tolerability of PD-1 Antibody SHR-1210 in Patients With Advanced Solid Tumors

NCT02742935 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT02742935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02742935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study on the Safety and Tolerability of PD-1 Antibody SHR-1210 in Patients With Advanced Solid Tumors
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 27, 2016
Completion date
May 6, 2019
Enrollment
99 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, solid tumor